Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
HALO Halozyme Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: HALO
Price (delayed)
$55.27
Market cap
$6.81B
P/E Ratio
14.36
Dividend/share
N/A
EPS
$3.85
Enterprise value
$8.14B
Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in
Highlights
The company's equity has surged by 171% YoY and by 33% QoQ
HALO's EPS has surged by 57% year-on-year and by 10% since the previous quarter
Key stats
What are the main financial stats of HALO
Market
Valuations
Earnings
Shares outstanding
123.22M
Market cap
$6.81B
Enterprise value
$8.14B
Price to earnings (P/E)
14.36
Price to book (P/B)
14.11
Price to sales (P/S)
6.28
EV/EBIT
13.07
EV/EBITDA
11.55
EV/Sales
7.51
Revenue
$1.08B
Gross profit
$904.82M
Operating income
$597.47M
Net income
$485.36M
EBIT
$623.05M
EBITDA
$704.6M
Free cash flow
$495.76M
Per share
Balance sheet
Liquidity
EPS
$3.85
EPS diluted
$3.76
Free cash flow per share
$4.02
Book value per share
$3.92
Revenue per share
$8.8
TBVPS
$11.33
Total assets
$2.2B
Total liabilities
$1.71B
Debt
$1.51B
Equity
$482.27M
Working capital
$1.11B
Debt to equity
3.13
Current ratio
8.39
Quick ratio
7
Net debt/EBITDA
1.89
Margins
Efficiency
Dividend
EBITDA margin
65%
Gross margin
83.4%
Net margin
44.8%
Operating margin
55.1%
Return on assets
23.3%
Return on equity
122.2%
Return on invested capital
25.2%
Return on capital employed
30.4%
Return on sales
57.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HALO stock price
How has the Halozyme Therapeutics stock price performed over time
Intraday
1.94%
1 week
4.44%
1 month
1.88%
1 year
5.18%
YTD
15.6%
QTD
6.25%
Financial performance
How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$1.08B
Gross profit
$904.82M
Operating income
$597.47M
Net income
$485.36M
Gross margin
83.4%
Net margin
44.8%
The company's operating income has surged by 58% YoY and by 8% QoQ
HALO's net income has surged by 52% year-on-year and by 9% since the previous quarter
HALO's gross profit is up by 34% YoY and by 6% QoQ
The company's revenue rose by 26% YoY and by 7% QoQ
Price vs fundamentals
How does HALO's price correlate with its fundamentals
Growth
What is Halozyme Therapeutics's growth rate over time
Valuation
What is Halozyme Therapeutics stock price valuation
P/E
14.36
P/B
14.11
P/S
6.28
EV/EBIT
13.07
EV/EBITDA
11.55
EV/Sales
7.51
HALO's EPS has surged by 57% year-on-year and by 10% since the previous quarter
The stock's price to earnings (P/E) is 51% less than its 5-year quarterly average of 28.8 and 18% less than its last 4 quarters average of 17.2
The company's equity has surged by 171% YoY and by 33% QoQ
HALO's price to book (P/B) is 62% lower than its 5-year quarterly average of 36.5 and 23% lower than its last 4 quarters average of 18.0
The price to sales (P/S) is 42% lower than the 5-year quarterly average of 10.7 and 13% lower than the last 4 quarters average of 7.1
The company's revenue rose by 26% YoY and by 7% QoQ
Efficiency
How efficient is Halozyme Therapeutics business performance
The ROE has contracted by 37% YoY and by 12% from the previous quarter
Halozyme Therapeutics's return on assets has increased by 33% YoY and by 5% QoQ
HALO's return on invested capital is up by 29% year-on-year and by 4.1% since the previous quarter
HALO's return on sales is up by 21% year-on-year
Dividends
What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HALO.
Financial health
How did Halozyme Therapeutics financials performed over time
The company's total assets is 28% higher than its total liabilities
Halozyme Therapeutics's quick ratio has increased by 40% YoY and by 8% from the previous quarter
The company's current ratio rose by 26% YoY and by 8% QoQ
The company's equity has surged by 171% YoY and by 33% QoQ
Halozyme Therapeutics's debt to equity has plunged by 63% YoY and by 24% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.